RedHill Biopharma (RDHL) Cash & Equivalents (2011 - 2025)

RedHill Biopharma (RDHL) has reported Cash & Equivalents for 15 consecutive years, with $4.0 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 13.99% year-over-year to $4.0 million in Q4 2025; TTM through Dec 2025 was $4.0 million, a 13.99% decrease from a year earlier, with the FY2025 full-year figure at $4.0 million, down 13.99% from the prior year.
• Cash & Equivalents was $4.0 million for Q4 2025 at RedHill Biopharma, up from $2.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $76.0 million in Q1 2021 and troughed at $2.9 million in Q2 2025.
• A 5-year average of $25.9 million and a median of $20.0 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents jumped 78.53% in 2021 and plunged 72.11% in 2023, its largest moves.
• Over 5 years, Cash & Equivalents stood at $29.5 million in 2021, then slumped by 32.25% to $20.0 million in 2022, then sank by 72.11% to $5.6 million in 2023, then dropped by 17.09% to $4.6 million in 2024, then decreased by 13.99% to $4.0 million in 2025.
• The last three Cash & Equivalents figures came in at $4.0 million (Q4 2025), $2.9 million (Q2 2025), and $4.6 million (Q4 2024), per Business Quant data.